Ulcerative Colitis (UC)Early Phase 1NCT06853522
hucMSCs Exosomes for the Treatment of Active Ulcerative Colitis
A Early Phase 1 study testing exosomes derived from human umbilical cord mesenchymal stem cells and saline +5% albumin in people with Ulcerative Colitis (UC), run by Shanghai East Hospital at 1 site in China.
Trial summary
To evaluate the safety and efficacy of hUC-MSCs-Exos in the treatment of ulcerative colitis. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Ulcerative Colitis (UC)
- What is being tested?
- exosomes derived from human umbilical cord mesenchymal stem cells and saline +5% albumin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteChina
- Study dates
- 30 May 2025to 4 Apr 2028
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects have had UC for at least 3 months (since symptom onset). The diagnosis should be confirmed by clinical and endoscopic evidence and confirmed by histopathological reports (note: if no previous reports are available, endoscopy and histopathology may be performed at the time of screening).
- Subjects had active UC, defined as four-component Mayo score of 6-12 (inclusive), endoscopy score ≥2, rectal bleeding score ≥1, and bowel frequency score ≥1.
- 18 to 75 years old, weight ≥40 kg
- Meet at least one of the following a/b/c criteria: a. inadequate or non-response to one or more of the following treatments: i) oral prednisone ≥40mg/ day (or equivalent) or budesonide ≥9mg/ day or equivalent or beclomethasone ≥5mg/ day for at least 2 weeks. ii) At least 8 weeks of immunomodulators (AZA≥2 mg/kg/ day or 6-MP≥1.0mg/kg/ day [or lower doses, but 6-thioguanine nucleotides with therapeutic concentrations recorded]). iii) Oral administration of aminosalicylate (e.g. Mesalazine, salazine sulfopyridine, oxalazine, balsalazine) in accordance with the dosage and duration of the applicable local instructions. iv) The frontier therapy for UC has completed at least the induction dosing regimen, At doses greater than or equal to the approved instructions: anti-TNF anti-integrins (e.g., Vederizumab), JAK inhibitors (e.g., Tofaciib, Upatinib, or filgotinib), anti-IL-23 or anti-IL-12/23 drugs for the treatment of UC (e.g., ulinumab), S1PR modulators (e.g., ozamod) b. Corticosteroid dependence: failure to taper successfully to <10mg/ day of prednisone or equivalent or <6mg/ day of budesonide or <5mg/ day of beclometasone within 3 months of starting treatment (i.e., disease onset), or relapse occurs within 3 months of stopping corticosteroids. c. Intolerance to 1 or 2 of the following treatments (e.g., inability to reach the therapeutic dose or duration of treatment due to dose-limiting adverse reactions) i) corticosteroids: Adverse reactions associated with dose-limiting therapy may include, but are not limited to, infections, hyperglycemia, osteoporosis, insomnia, or psychiatric disorders. ii) Immunomodulators: Adverse reactions associated with dose-restricted therapeutic administration may include, but are not limited to, infection, nausea/vomiting, fatigue, myelosuppression, or liver toxicity.
- Being treated with any of the following permitted drugs during the study period and meeting the drug stabilization requirements (if applicable): a. Oral corticosteroids must be stable for at least 2 weeks before randomization at an equivalent dose of ≤20 mg prednisone or ≤9mg budesonide or ≤5mg beclomethasone per day. b. A steady dose of oral aminosalicylate should be maintained for at least 2 weeks before randomization. c.AZA, 6-MP, or MTX(≤15 mg/ week) should be maintained at a stable dose for at least 4 weeks before randomization.
- Participate voluntarily and sign a written informed consent. -
Who cannot join
- Diagnosis of CD or undefined colitis (IBD- undefined) or other types of colitis or enteritis that may confuse assessment of effectiveness.
- The current diagnosis is explosive colitis and/or toxic megacolon.
- Had received fecal microbial transplantation within 4 weeks prior to randomization.
- Had been hospitalized for UC within 2 weeks prior to screening.
- There is clear evidence of past or current low or high grade colon dysplasia, including dysplasia detected during screening colonoscopy that has not been completely resectable.
- Have any active or severe infection that does not resolve after adequate treatment.
Show all 11Show fewer
- Hepatitis B, hepatitis C virus infection, tuberculosis, HIV, uncontrollable diabetes, mental illness.
- Have undergone organ transplantation requiring sustained immunosuppressive therapy.
- A history of cancer within the past 5 years (except for completely treated non-melanoma skin cell carcinoma or carcinoma in situ of the cervix after complete surgical removal). Subjects who have had a diagnostic evaluation that suggests malignancy (e.g., chest or breast imaging) and who cannot reasonably rule out malignancy after additional clinical evaluation will be excluded from this study.
- A history of drug or alcohol abuse in the 6 months prior to screening (as reported by the subject).
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120
Lan Zhong, 13162099450, lanzhong@tongji.edu.cn
About this study
Official title: A Randomized, Single-blind Clinical Study of Human Umbilical Cord Mesenchymal Stem Cell Exosomes for the Treatment of Moderate-to-severe Active Ulcerative Colitis After Existing Therapy Failure
To evaluate the safety and efficacy of hUC-MSCs-Exos in the treatment of ulcerative colitis.
Read the detailed description
A large number of previous studies and literature data collection have demonstrated the efficacy of hUC-MSCs-Exos in animal models of inflammatory bowel disease, so the investigators will further verify the safety and effectiveness of hUC-MSCs-Exos in the treatment of UC patients, and provide new ideas for clinical treatment of UC.
- Conditions
- Ulcerative Colitis (UC)
- Being tested
- exosomes derived from human umbilical cord mesenchymal stem cells, saline +5% albumin
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
exosomes derived from human umbilical cord mesenchymal stem cellsDrug
Also called exosomes
The corresponding exosome content of 60×10^6 umbilical cord mesenchymal stem cells was given
saline +5% albuminDrug
Also called placebo
Equal amount of saline +5% albumin was given
| Study group | Role | What they receive |
|---|---|---|
| Exos Localized Treatment Group | Experimental | The corresponding exosome content of 60×10^6 umbilical cord mesenchymal stem cells was given Receives: Drug: exosomes derived from human umbilical cord mesenchymal stem cells |
| Placebo Localized Treatment Group | Placebo comparator | Equal amount of saline +5% albumin Receives: Drug: saline +5% albumin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mayo Score
The complete Mayo Score consists of four assessments, each scored on a scale of 0 to 3: stool frequency, rectal bleeding, endoscopy, and the physician's global assessment (PGA) of disease activity. The endoscopy subscore of the complete Mayo Score is derived from the central reading of endoscopy results by a qualified central laboratory. Patient-reported stool frequency and rectal bleeding, as well as the PGA reported by the clinician, will be collected in an electronic diary.
Measured: Baseline, 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Secondary outcomes (25)
Geboes Score
It is the most commonly used histological scoring system for colonic mucosa in the field of ulcerative colitis (UC). It is divided into six grades: 1) Structural changes (Grade 0); 2) Chronic inflammatory infiltration (Grade 1); 3) Neutrophils and eosinophils in the lamina propria (Grade 2); 4) Neutrophils in the epithelium (Grade 3); 5) Crypt destruction (Grade 4); 6) Erosion or ulceration (Grade 5). Each grade is further divided into four subcategories. The Geboes score ranges from 0 to 5.4, with higher scores indicating more severe inflammation. Typically, active histological inflammation in UC is defined as a Geboes score of ≥2B.1.
Measured: Baseline, at 12 weeks after treatment.
Inflammatory Bowel Disease Questionnaire (IBDQ)
The IBDQ is a well-established assessment tool for measuring disease-specific health-related quality of life. It consists of 32 items : bowel symptoms (10 items), systemic symptoms (5 items), emotional functioning (12 items), and social functioning (5 items). The questionnaire is scored using a 7-point Likert scale, ranging from worst health (1) to best health (7). Domain scores are calculated by summing the item responses, with higher values indicating better quality of life.The total score range of the IBDQ is 32-224, which can be obtained by adding up the scores of individual domains. According to the total score, a meaningful change in the IBDQ score (also defined as an IBDQ response) is defined as a change of ≥ 16 points, and this threshold has been applied in studies involving subjects with Crohn's disease (CD) or ulcerative colitis (UC). In addition, IBDQ remission can be defined as a total score of ≥ 170 points.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
The item of urgency to defecate
Subjects are required to complete a single item that assesses how frequently they needed to empty their bowels immediately to avoid an accident in the past 7 days. The response scale ranges from 0 (never) to 4 (more than once a day).
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
EQ-5D-5L
The EQ-5D-5L is a brief self-report measure of health status and function. The descriptive system of this instrument includes 5 items for measuring problems (none, mild, moderate, severe, or extreme), covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In total, the responses to these items describe 5^5 = 3,125 health states. The responses of the subjects to the 5 items can be weighted and aggregated to generate a utility index score that measures the social value of their current health. These scores range from 1 (perfect health) to 0 (death), and negative values indicate a health state worse than death. Additionally, the EQ-5D-5L includes a Visual Analogue Scale (VAS), which allows subjects to rate their current health on a scale from 0 (worst imaginable health) to 100 (best imaginable health).
Among patients receiving treatment for IBD, a meaningful change in the EQ-5D-5L VAS score is defined as a change of ≥ 10 points.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
CRP (C - reactive protein)
The unit for CRP is milligrams per liter (mg/L), with the normal reference value typically being ≤10 mg/L.When there is a bacterial infection, the CRP level usually increases significantly, which can exceed 100 mg/L, or even be higher. In contrast, when there is a viral infection, the CRP level generally does not increase or only increases slightly, usually not exceeding 50 mg/L. Therefore, CRP testing can be used to distinguish between bacterial infections and viral infections. The CRP level is positively correlated with the severity of the infection. The more severe the infection is, the more obvious the increase in CRP will be. By monitoring the changes in the CRP level, the therapeutic effect of the infection treatment and the progression of the disease can be evaluated.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
fecal calprotectin
The unit for fecal calprotectin is micrograms per gram of stool (μg/g), with a normal range of 0-50 μg/g. Values exceeding this range may indicate intestinal inflammation or disease activity (such as in inflammatory bowel disease).
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
immune cell subsets
The detection of immune cell subsets (such as T cells, B cells, and NK cells) is usually expressed as a percentage (%).
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
BMI (Body Mass Index)
The unit is kilograms per square meter (kg/m²). It is calculated using the formula: weight (kg) ÷ height² (m²). Normal range: 18.5-24 kg/m² (for adults).
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
albumin
The unit is grams per liter (g/L). It reflects liver synthetic function and nutritional status. Normal reference values are 35-50 g/L for adults and 34-48 g/L for individuals aged 60 years or older.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Hemoglobin
The unit is grams per liter (g/L). It is used to assess anemia or polycythemia. Normal reference values are as follows: adult males: 120-160 g/L; adult females: 110-150 g/L.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
body temperature
The unit is degrees Celsius (℃). Normal range: axillary temperature is 36℃ to 37℃.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Respiratory Rate
The unit is breaths per minute (breaths/min). Normal range: adults, 16-20 breaths/min (at rest).Tachypnea may be caused by reasons such as pneumonia, fever, cardiovascular diseases, anemia, etc., while bradypnea may be caused by reasons such as increased intracranial pressure, hypothyroidism, etc.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Blood Pressure
The unit is millimeters of mercury (mmHg). Normal range: systolic pressure, 90-139 mmHg; diastolic pressure, 60-89 mmHg.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Heart Rate
The unit is beats per minute (beats/min). Normal range: 60-100 beats/min (at rest).
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Blood White Blood Cells
Normal range for adults is 4.0-10.0×10⁹/L. An elevated level may indicate bacterial infection or inflammation, while a decreased level may be associated with viral infections or drug reactions.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Bloos Red Blood Cells
Normal range is 4.3-5.8×10¹²/L for males and 3.8-5.1×10¹²/L for females.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Platelets
Normal range is 125-350×10⁹/L. A reduced count increases the risk of bleeding, while an elevated count increases the risk of thrombosis.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Urine White Blood Cells
The reference value of white blood cells is 0 to 5 cells per high-power field (HP). If the number of white blood cells in each high-power field exceeds 5, it is called pyuria under the microscope, which suggests the possible presence of infections or other pathological changes in the urinary system.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Urine Red Blood Cells
Under normal circumstances, the number of urinary red blood cells is 0-3 per high-power field (HP). If the number of urinary red blood cells in each high-power field exceeds 3, it is called microscopic hematuria.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Urinary Protein
Normal value is negative (-).The test results of urinary protein are affected by various factors. For example, strenuous exercise, fever, a high-protein diet, etc., may all lead to a transient increase in physiological urinary protein, which can return to normal after removing the influencing factors. It may also indicate the presence of kidney diseases and other conditions.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
occult blood test (OB)
Normally, the result is negative. A positive result is commonly seen in hemorrhagic diseases of the digestive tract.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
alanine aminotransferase (ALT)
Normal range is 7-40 U/L. Elevated levels indicate liver damage.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
aspartate aminotransferase (AST)
Normal range is 13-35 U/L. Elevated levels indicate liver damage.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
serum creatinine (Cr)
Normal range is 53-106 μmol/L for males and 44-97 μmol/L for females. Elevated levels suggest decreased renal function.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Blood Urea Nitrogen (BUN)
Normal range is 2.9-7.5 mmol/L. Elevated levels may be associated with renal failure or dehydration.
Measured: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2025
- Study start30 May 2025 (estimated)
- Primary completion4 Apr 2027 (estimated)
- Study completion4 Apr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative Colitis (UC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai East Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06853522
- Sponsor's protocol ID
- 2025YS-004
- Status last verified
- Feb 2025
- First submitted
- 13 Feb 2025
- Last updated
- 27 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Single-blind Clinical Study of Human Umbilical Cord Mesenchymal Stem Cell Exosomes for the Treatment of Moderate-to-severe Active Ulcerative Colitis After Existing Therapy Failure
- ClinicalTrials.gov ID
- NCT06853522
- Acronym / sponsor ID
- 2025YS-004
- Conditions
- Ulcerative Colitis (UC)
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Shanghai East HospitalUniversity, hospital or other
- Study start
- 30 May 2025 (estimated)
- Primary completion
- 4 Apr 2027 (estimated)
- Study completion
- 4 Apr 2028 (estimated)
- First posted
- 3 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the safety and efficacy of hUC-MSCs-Exos in the treatment of ulcerative colitis.
Detailed description
A large number of previous studies and literature data collection have demonstrated the efficacy of hUC-MSCs-Exos in animal models of inflammatory bowel disease, so the investigators will further verify the safety and effectiveness of hUC-MSCs-Exos in the treatment of UC patients, and provide new ideas for clinical treatment of UC.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Exos Localized Treatment Group | Experimental | Drug: exosomes derived from human umbilical cord mesenchymal stem cellsThe corresponding exosome content of 60×10^6 umbilical cord mesenchymal stem cells was given |
| Placebo Localized Treatment Group | Placebo comparator | Drug: saline +5% albuminEqual amount of saline +5% albumin |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Subjects have had UC for at least 3 months (since symptom onset). The diagnosis should be confirmed by clinical and endoscopic evidence and confirmed by histopathological reports (note: if no previous reports are available, endoscopy and histopathology may be performed at the time of screening).
- Subjects had active UC, defined as four-component Mayo score of 6-12 (inclusive), endoscopy score ≥2, rectal bleeding score ≥1, and bowel frequency score ≥1.
- 18 to 75 years old, weight ≥40 kg
- Meet at least one of the following a/b/c criteria: a. inadequate or non-response to one or more of the following treatments: i) oral prednisone ≥40mg/ day (or equivalent) or budesonide ≥9mg/ day or equivalent or beclomethasone ≥5mg/ day for at least 2 weeks. ii) At least 8 weeks of immunomodulators (AZA≥2 mg/kg/ day or 6-MP≥1.0mg/kg/ day [or lower doses, but 6-thioguanine nucleotides with therapeutic concentrations recorded]). iii) Oral administration of aminosalicylate (e.g. Mesalazine, salazine sulfopyridine, oxalazine, balsalazine) in accordance with the dosage and duration of the applicable local instructions. iv) The frontier therapy for UC has completed at least the induction dosing regimen, At doses greater than or equal to the approved instructions: anti-TNF anti-integrins (e.g., Vederizumab), JAK inhibitors (e.g., Tofaciib, Upatinib, or filgotinib), anti-IL-23 or anti-IL-12/23 drugs for the treatment of UC (e.g., ulinumab), S1PR modulators (e.g., ozamod) b. Corticosteroid dependence: failure to taper successfully to <10mg/ day of prednisone or equivalent or <6mg/ day of budesonide or <5mg/ day of beclometasone within 3 months of starting treatment (i.e., disease onset), or relapse occurs within 3 months of stopping corticosteroids. c. Intolerance to 1 or 2 of the following treatments (e.g., inability to reach the therapeutic dose or duration of treatment due to dose-limiting adverse reactions) i) corticosteroids: Adverse reactions associated with dose-limiting therapy may include, but are not limited to, infections, hyperglycemia, osteoporosis, insomnia, or psychiatric disorders. ii) Immunomodulators: Adverse reactions associated with dose-restricted therapeutic administration may include, but are not limited to, infection, nausea/vomiting, fatigue, myelosuppression, or liver toxicity.
- Being treated with any of the following permitted drugs during the study period and meeting the drug stabilization requirements (if applicable): a. Oral corticosteroids must be stable for at least 2 weeks before randomization at an equivalent dose of ≤20 mg prednisone or ≤9mg budesonide or ≤5mg beclomethasone per day. b. A steady dose of oral aminosalicylate should be maintained for at least 2 weeks before randomization. c.AZA, 6-MP, or MTX(≤15 mg/ week) should be maintained at a stable dose for at least 4 weeks before randomization.
Key exclusion criteria (11 listed)
- Diagnosis of CD or undefined colitis (IBD- undefined) or other types of colitis or enteritis that may confuse assessment of effectiveness.
- The current diagnosis is explosive colitis and/or toxic megacolon.
- Had received fecal microbial transplantation within 4 weeks prior to randomization.
- Had been hospitalized for UC within 2 weeks prior to screening.
- There is clear evidence of past or current low or high grade colon dysplasia, including dysplasia detected during screening colonoscopy that has not been completely resectable.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| exosomes derived from human umbilical cord mesenchymal stem cellsAlso: exosomesThe corresponding exosome content of 60×10^6 umbilical cord mesenchymal stem cells was given | Drug | Exos Localized Treatment Group |
| saline +5% albuminAlso: placeboEqual amount of saline +5% albumin was given | Drug | Placebo Localized Treatment Group |
Primary outcome
Mayo Score
Time frame: Baseline, 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
The complete Mayo Score consists of four assessments, each scored on a scale of 0 to 3: stool frequency, rectal bleeding, endoscopy, and the physician's global assessment (PGA) of disease activity. The endoscopy subscore of the complete Mayo Score is derived from the central reading of endoscopy results by a qualified central laboratory. Patient-reported stool frequency and rectal bleeding, as well as the PGA reported by the clinician, will be collected in an electronic diary.
25 secondary outcomes
Geboes Score
Time frame: Baseline, at 12 weeks after treatment.
Inflammatory Bowel Disease Questionnaire (IBDQ)
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
The item of urgency to defecate
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
EQ-5D-5L
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
CRP (C - reactive protein)
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
fecal calprotectin
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
immune cell subsets
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
BMI (Body Mass Index)
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
albumin
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Hemoglobin
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
body temperature
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Respiratory Rate
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Blood Pressure
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Heart Rate
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Blood White Blood Cells
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Bloos Red Blood Cells
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Platelets
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Urine White Blood Cells
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Urine Red Blood Cells
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Urinary Protein
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
occult blood test (OB)
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
alanine aminotransferase (ALT)
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
aspartate aminotransferase (AST)
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
serum creatinine (Cr)
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Blood Urea Nitrogen (BUN)
Time frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Ulcerative Colitis (UC)
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
Not yet recruitingObservational study
Non-Invasive Biomarker Monitoring in UC on Biologics
Ulcerative Colitis
RecruitingPhase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ulcerative Colitis (UC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing exosomes derived from human umbilical cord mesenchymal stem cells and saline +5% albumin in people with Ulcerative Colitis (UC), run by Shanghai East Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lan Zhong (13162099450, lanzhong@tongji.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mayo Score (time frame: Baseline, 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2025.